Clinical Trial Update: First in Human, Dose Escalation, Dose Expansion Study of AUR105 [Phase 1]

View source ↗

Summary

AUR105 is Aurigene's first-in-human Phase 1 study with dose-escalation and dose-expansion cohorts in adults with solid tumors and lymphomas. The trial (NCT05605…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• AUR105

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: Solid Tumor, Adult, Non-hodgkin Lymphoma | Phase 1 | Status: TERMINATED